Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Monness, Crespi, Hardt Downgrades Salesforce to Neutral

Monness, Crespi, Hardt Downgrades Salesforce to Neutral

Monness, Crespi, Hardt analyst Brian White downgrades Salesforce (NYSE:CRM) from Buy to Neutral.

byBenzinga Newsdesk

November 17, 2022

1 minute read

Monness, Crespi, Hardt analyst Brian White downgrades Salesforce (NYSE:CRM) from Buy to Neutral.

Analyst Ratings

Analyst Expectations for Surgery Partners’s Future

By Benzinga Insights

July 31, 12:00 PM

Within the last quarter, Surgery Partners (NASDAQ:SGRY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

SGRY

Needham Maintains Buy on Pliant Therapeutics, Raises Price Target to $45

By Benzinga Newsdesk

January 23, 1:18 PM

Needham analyst Joseph Stringer maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and raises the price target from $40 to $45.

PLRX

Nuvation Bio Q4 EPS $(0.10) Beats $(0.11) Estimate

By Happy Mohamed

March 15, 4:23 PM

Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 16.67 percent increase over losses of $(0.12) per share from the

NUVB

Oppenheimer Assumes Cellectar Biosciences at Outperform, Announces Price Target of $5.5

By Benzinga Newsdesk

July 18, 10:35 AM

Oppenheimer analyst Jeff Jones assumes Cellectar Biosciences (NASDAQ:CLRB) with a Outperform rating and announces Price Target of $5.5.

CLRB

Monness, Crespi, Hardt Downgrades Salesforce to Neutral

Related Posts

Analyst Expectations for Surgery Partners’s Future

Needham Maintains Buy on Pliant Therapeutics, Raises Price Target to $45

Nuvation Bio Q4 EPS $(0.10) Beats $(0.11) Estimate

Oppenheimer Assumes Cellectar Biosciences at Outperform, Announces Price Target of $5.5